He, S;
Mansour, MR;
Zimmerman, MW;
Ki, DH;
Layden, HM;
Akahane, K;
Gjini, E;
... Look, AT; + view all
(2016)
Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain.
eLife
, 5
, Article e14. 10.7554/eLife.14713.
Preview |
Text
Mansour_elife-14713-v2.pdf - Published Version Download (5MB) | Preview |
Abstract
Earlier reports showed that hyperplasia of sympathoadrenal cell precursors during embryogenesis in Nf1-deficient mice is independent of Nf1’s role in down-modulating RAS-MAPK signaling. We demonstrate in zebrafish that nf1 loss leads to aberrant activation of RAS signaling in MYCN-induced neuroblastomas that arise in these precursors, and that the GTPase-activating protein (GAP)-related domain (GRD) is sufficient to suppress the acceleration of neuroblastoma in nf1-deficient fish, but not the hypertrophy of sympathoadrenal cells in nf1 mutant embryos. Thus, even though neuroblastoma is a classical “developmental tumor”, NF1 relies on a very different mechanism to suppress malignant transformation than it does to modulate normal neural crest cell growth. We also show marked synergy in tumor cell killing between MEK inhibitors (trametinib) and retinoids (isotretinoin) in primary nf1a-/- zebrafish neuroblastomas. Thus, our model system has considerable translational potential for investigating new strategies to improve the treatment of very high-risk neuroblastomas with aberrant RAS-MAPK activation.
Type: | Article |
---|---|
Title: | Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.7554/eLife.14713 |
Publisher version: | http://dx.doi.org/10.7554/eLife.14713 |
Language: | English |
Additional information: | Copyright He et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited. |
Keywords: | CHILDRENS ONCOLOGY GROUP, HIGH-RISK NEUROBLASTOMA, MYELOABLATIVE THERAPY, 13-CIS-RETINOIC ACID, TUMOR INITIATION, GENE, ZEBRAFISH, MUTATIONS, AMPLIFICATION, SUPPRESSOR |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > UCL GOS Institute of Child Health > Developmental Biology and Cancer Dept |
URI: | https://discovery.ucl.ac.uk/id/eprint/1494559 |
Archive Staff Only
View Item |